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Abstract. 
 
The integral ER membrane protein HMG-
CoA reductase (HMGR) is a key enzyme of the me-
valonate pathway from which sterols and other essen-
tial molecules are produced. HMGR degradation oc-
curs in the ER and is regulated by mevalonate-derived 
signals. Little is known about the mechanisms respon-
sible for regulating HMGR degradation. The yeast 
Hmg2p isozyme of HMGR undergoes regulated degra-
dation in a manner very similar to mammalian HMGR, 
allowing us to isolate mutants deﬁcient in regulating 
Hmg2p stability. We call these mutants 
 
cod
 
 mutants for 
the control of HMG-CoA reductase degradation. With 
this screen, we have identiﬁed the ﬁrst gene of this class, 
 
COD1
 
, which encodes a P-type ATPase and is identical 
to 
 
SPF1
 
. Our data suggested that Cod1p is a calcium 
transporter required for regulating Hmg2p degrada-
tion. This role for Cod1p is distinctly different from that 
 
of the well-characterized Ca
 
2
 
1
 
 P-type ATPase Pmr1p 
which is neither required for Hmg2p degradation nor 
its control. The identiﬁcation of Cod1p is especially in-
triguing in light of the role Ca
 
2
 
1
 
 plays in the regulated 
degradation of mammalian HMGR.
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2
 
1
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Introduction
 
The ER resident, integral membrane protein, hydroxy-
methylglutaryl-coenzyme A reductase (HMGR)
 
1
 
, cata-
lyzes the first committed step of the mevalonate pathway
from which sterols and other essential isoprenoids are pro-
duced. HMGR is subject to numerous modes of regula-
tion, including feedback control of HMGR stability (Ed-
wards et al., 1983; Chun et al., 1990; Goldstein and Brown,
1990). Increased production of mevalonate pathway prod-
ucts causes an increase in the degradation rate of HMGR
and a lowered steady-state level of the protein (Edwards
et al., 1983). Conversely, decreased production of pathway
products causes a decrease in the degradation rate of
HMGR and an elevated steady-state level of the protein.
The mevalonate-derived molecules that control the stabil-
ity of HMGR are poorly defined, and the mechanisms by
which these signals control HMGR stability remain un-
known (Roitelman and Simoni, 1992; Keller et al., 1996;
Meigs et al., 1996; Lopez et al., 1997; Meigs and Simoni,
1997).
The yeast HMGR isozyme Hmg2p undergoes regulated
degradation with many similarities to the mammalian en-
zyme, including control by a signal derived from the me-
valonate pathway product farnesyl pyrophosphate FPP
(Hampton and Rine, 1994; Hampton and Bhakta, 1997;
Gardner and Hampton 1999a). We have identified genes
required for the degradation of Hmg2p, referred to as
 
HRD 
 
genes (pronounced “herd”, for HMG-CoA reduc-
tase degradation). The 
 
HRD 
 
genes are also required for
the degradation of numerous other proteins, none of
which are regulated by the mevalonate pathway (Wil-
hovsky et al., 2000; Hiller et al., 1996; Bordallo et al., 1998;
Galan et al., 1998; Plemper et al., 1998).
Our studies suggest that regulation of Hmg2p stability
does not occur by modulation of the 
 
HRD-
 
encoded degra-
dation machinery (Hampton et al., 1996a; Gardner and
Hampton, 1999b). Rather, we posit that separate genes are
required for specifically regulating degradation (see Fig.
1). We refer to these regulatory genes as 
 
COD
 
 genes, for
the control of HMG-CoA reductase degradation. 
 
cod
 
 mu-
tants deficient in regulation of Hmg2p degradation could
fall into two phenotypic classes. Those in which Hmg2p is
constitutively stable even when the degradation machin-
ery is intact, and those in which Hmg2p is constitutively
degraded even when degradation signals are low. This sec-
ond class of mutants is the subject of this work. These mu-
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tants would allow degradation of Hmg2p in the presence
of drugs such as lovastatin, an inhibitor of HMGR, that
normally slow degradation by decreasing production of
the signal. By our model (see Fig. 1), Hmg2p degradation
in this type of 
 
cod
 
 mutant should still be blocked by 
 
hrd
 
mutations (see Fig. 1).
We have isolated the first 
 
cod
 
 mutant and cloned the
relevant gene, 
 
COD1
 
. The 
 
cod1-1 
 
mutant failed to prop-
erly regulate Hmg2p degradation but did not generally af-
fect the degradation of ER proteins. 
 
COD1
 
 was identical
to 
 
SPF1
 
, a gene previously identified in an unrelated
screen (Suzuki and Shimma, 1999). Cod1p belongs to a
large family of P-type ATPases involved in ion transport.
From the results presented below, we hypothesize that
Cod1p
 
 
 
effects the control of Hmg2p degradation through
acting on Ca
 
2
 
1
 
 levels in the ER.
 
Materials and Methods
 
Materials
 
Restriction enzymes, Vent DNA polymerase and T4 DNA ligase were ob-
tained from New England Biolabs. Lovastatin, L659,699 and zaragozic
acid were generously provided by Dr. James Bergstrom (Merck, Rahway,
NJ). Ro48-8071 was a gift from Dr. Olivier Morand (F. Hoffman-
LaRoche). The 9E10 cell culture supernatant was produced in our lab
from cells (CRL 1729; American Type Culture Collection) grown in
RPMI1640 culture medium (GIBCO BRL) with 10% fetal calf serum and
supplements. 12CA5 anti-HA antibody was obtained from Dr. Don Rio
(UC Berkeley, Berkeley, CA). Affinity-purified HRP-conjugated goat
anti–mouse antibodies were purchased from Sigma. ECL chemilumines-
cence immunodetection reagents were from Amersham. All other chemi-
cal reagents were obtained from Sigma or Fisher.
 
Plasmid Construction and DNA Manipulation
 
Plasmid pRH468 (integrating) expressed 1myc-Hmg2p from a GAPDH
promoter. pRH468 was constructed by removing the NcoI-AatII fragment
containing part of the 
 
URA3
 
 open reading frame from pRH423 (integrat-
ing, 
 
URA3
 
; Hampton and Bhakta, 1997). The Hmg2p-GFP reporter pro-
tein was expressed from plasmid pRH680 (integrating, 
 
LEU2
 
) or pRH469
(integrating, 
 
URA3
 
; Gardner et al., 1998). pRH680 was constructed from
pRH469 by replacing the AatII-ApaI segment of the 
 
URA3
 
 gene in
pRH469 with the AatII-ApaI fragment from pRS312 containing the
 
LEU
 
2 gene (Sikorski and Hieter, 1989). Hmg1p-GFP was expressed from
pRH475 (integrating, 
 
URA3
 
; Gardner et al., 1998).
Plasmid pRH397 (2
 
m
 
, 
 
URA3
 
) expressed HA-tagged ubiquitin from the
GAPDH promoter and was constructed as follows. The HA-ubiquitin
coding region was excised from YEp112 (Ellison and Hochstrasser, 1991)
with EcoRI-ClaI and cloned into the same sites in Bluescript KS II to
make pRH381. The HA-ubiquitin coding region was then cloned as a
BamHI-ClaI fragment into the same sites of pRH98-3 (2
 
m
 
, 
 
URA3
 
; Donald
et al., 1997) to yield pRH397.
Plasmids pRH810 (ARS/CEN, 
 
LEU2
 
) and pRH811 (2
 
m
 
, 
 
LEU2
 
) ex-
pressed 
 
COD1
 
. 
 
COD1
 
 was amplified from yeast genomic DNA by PCR
along with 300 bp of flanking sequence. The PCR product was cloned into
the vector pCR2.1 (Invitrogen). The BamHI fragment containing 
 
COD1
 
was subcloned into YEp13 (2
 
m
 
, 
 
LEU2
 
; Broach et al., 1979) to generate
pRH811 or into pRS315 (ARS/CEN, 
 
LEU2
 
;
 
 
 
Sikorski and Hieter, 1989) to
generate pRH810.
pCS186, used for disruption of the 
 
COD1/SPF1 
 
open reading frame,
was provided by Chise Suzuki (National Food Research Institute,
Tsukuba, Japan; Suzuki and Shimma, 1999).
 
Yeast Culture and Strains
 
Yeast strains were grown in minimal media (Difco Yeast Nitrogen Base
without Amino Acids) with glucose and the appropriate supplements as
described previously, except that leucine supplementation was increased
to 60 mg/liter (Hampton and Rine, 1994). Experiments were performed in
minimal media at 30
 
8
 
C unless otherwise noted. For experiments with
 
EGTA, strains were grown in YNB without CaCl
 
2
 
 from Bio 101, Inc. buff-
ered with potassium MES to pH 6.5. Yeast was transformed with plasmid
DNA using the LiOAC method (Ito et al., 1983). The parental genotype
of all of the yeast strains used in this study was 
 
MATa ade2-101, his3-
 
D
 
200,
lys2-801, met, hmg1::LYS, hmg2::HIS3, ura3-52, and leu2
 
D
 
. Only distin-
guishing mutations are listed in Table I and discussed below.
RHY541, the parent strain for the COD screen, expressed the reporter
proteins 1myc-Hmg2p and Hmg2p-GFP. RHY541 was constructed from
the mevalonate auxotrophic strain RHY468 by integration at the 
 
hmg2::
HIS3 
 
locus of plasmid pRH468 expressing 1myc-Hmg2p and selection for
mevalonate prototrophy. The resulting strain was then transformed with
pRH469 cut at the BsgI site and selected for uracil prototrophy to give the
RHY541 parent. Various genotypes of 
 
cod1-1
 
 were constructed by cross-
ing with appropriate isogenic strains and isolation of haploid progeny.
RHY1127 (
 
cod1-1/hrd1
 
D
 
) was constructed by crossing RHY911 (
 
cod1-1
 
)
with an isogenic strain with 
 
hrd1
 
D
 
::URA3, followed by sporulation and
recovery of RHY1127 as a meiotic segregant. RHY1076 (
 
cod1-1, ubc7
 
D
 
)
was made by crossing RHY911 to RHY1056 (
 
ubc7
 
D
 
). The 
 
ubc7
 
D
 
::URA3
 
allele carried by RHY1056 was made by PCR disruption with 
 
HIS3
 
 and
subsequent replacement of 
 
HIS3
 
 with 
 
URA3
 
 with pHU10 (Cross, 1997).
RHY1473 (
 
cod1-1
 
) and RHY1475 (
 
COD1
 
) expressed Hmg1p-GFP
from the GAPDH promoter. They were constructed in a cross of RHY911
to RHY550 (
 
ura3-52::URA3::HMG1::GFP
 
). RHY550 was constructed by
integrative transformation of RHY532 with pRH475 (integrating, 
 
URA3,
HMG1::GFP
 
).
RHY1203 (
 
cod1-1
 
) expressing K6R-Hmg2p-GFP was constructed by
plating RHY811 on 5-fluoro-orotic acid to remove pRH469, and sub-
sequent transformation with pRH671 (integrating,
 
 K6RHMG2::GFP,
URA3
 
; Gardner and Hampton, 1999a). The isogenic Cod
 
1
 
 strain
RHY1205 was recovered from a cross of RHY1203 to RHY872.
 
SPF1/COD1 
 
was disrupted by transformation of RHY791 with the
BamHI-NheI fragment from pCS186. A corresponding Cod
 
1
 
 strain
(RHY1232), was constructed by integrative transformation of RHY791
with linearized pCS186 to produce a strain with the 
 
cod1::LEU2
 
 disrup-
tion allele in tandem with functional 
 
COD1
 
. RHY2201, RHY2202,
RHY2203, and RHY2204 were constructed by transforming pRH469 into
CS601A, CS601B, CS601C, and CS601D, respectively (Suzuki and
Shimma, 1999).
The 
 
COD1 
 
paralogue YOR291w was deleted by transformation of the
haploid strain RHY791 with a KanMX disruption cassette with 40-bp
flanks homologous to the YOR291w locus (Wach et al., 1994). Disruption
was confirmed by PCR.
 
Optical Assays
 
The optical techniques used in this study are described in full detail else-
where (Cronin and Hampton, 1999). For assaying colony fluorescence, a
Kodak Carousel
 
®
 
 4400 slide projector with a 488-nm narrow bandpass fil-
ter (Omega Optical) placed in the slot for slides provided illumination.
Fluorescence of colonies was assessed visually with a long bandpass filter
(Kodak Wratten No. 12) to remove blue light.
Analysis of Hmg2p-GFP fluorescence by flow microfluorimetry was
performed on a Becton Dickinson FACScalibur
 
®
 
 flow microfluorimeter
and Cell Quest software. Strains were typically grown into early log phase
in minimal media. After addition of drugs, cultures were incubated 4 h be-
fore analysis. Data from 10,000 cells were used for each histogram. In flow
microfluorimetry experiments testing the effects of ions, cultures were in-
cubated in exogenous CaCl
 
2
 
 or other salt 
 
z
 
12 h before the addition of me-
valonate pathway inhibitors. For ion chelation experiments, EGTA was
added to a final concentration of 780 
 
m
 
M in cultures diluted to an optical
density of 0.001 at 600 nm 
 
z
 
12 h before the addition of mevalonate path-
way inhibitors. When indicated, MgCl
 
2 
 
or CaCl
 
2
 
 was added to EGTA-
treated cultures to a concentration of 1 mM simultaneously with meval-
onate pathway inhibitors, 4 h before analysis. For analysis by fluorescence
microscopy, cultures grown as described for flow microfluorimetry were
viewed using a Nikon Optiphot II microscope with a B2-A filter.
 
Cycloheximide Chase
 
To analyze regulated degradation directly, a cycloheximide chase fol-
lowed by lysis and immunoblotting was used as described previously
(Gardner et al., 1998).
 
Ubiquitination Assay
 
To aid in detection of ubiquitin, the strains tested were transformed with 
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plasmid pRH379 (2
 
m
 
, 
 
URA3
 
) that expressed HA epitope-tagged ubiquitin
from the GAPDH promoter. Ubiquitination of Hmg2p was assayed by
immunoprecipitation of Hmg2p followed by immunoblotting with 12CA5
anti-HA antibody to detect covalently linked ubiquitin and with 9E10
anti-MYC antibody to detect immunoprecipitated 1myc-Hmg2p, as de-
scribed previously (Gardner et al., 1998; Gardner and Hampton, 1999b).
 
Mutagenesis and COD Screen
 
EMS (methane sulfonic acid ethyl ester) mutagenesis was based on the
protocol of Lawrence (1991). Mutagenized RHY541 cells (75% killing by
EMS) were sequentially evaluated for four regulatory phenotypes. The
mutagenized cells were plated onto minimal solid medium supplemented
with 30 mg/liter adenine sulfate, 30 mg/liter methionine, and 12.5 
 
m
 
g/ml
lovastatin. The wild-type strain is normally bright when plated on this me-
dium due to lovastatin-induced stabilization of Hmg2p-GFP. After 3 d,
colonies were screened visually for low fluorescence compared with sur-
rounding colonies. Candidate 
 
cod 
 
mutants with low fluorescence were iso-
lated, rescreened for the optical phenotype, and then assayed for growth
sensitivity to 200 
 
m
 
g/ml lovastatin by replica plating. Patches of candidate
mutants were grown on YPD plates, then replica plated onto a YPD mas-
ter plate. The master plate was immediately replica plated onto minimal
plates with 200 
 
m
 
g/ml lovastatin and then onto minimal plates without lov-
astatin. This second dilution plating step insured low, uniform density of
test patches on the lovastatin plates. Candidates that were sensitive to 200
 
m
 
g/ml lovastatin were isolated from the YPD master plate. Dark, lova-
statin-sensitive candidates recovered from the no-drug master were next
tested directly for ability to regulate Hmg2p-GFP levels using flow micro-
fluorimetry as described above. Finally, candidates exhibiting poor regula-
tion of Hmg2p-GFP levels were assayed for regulation of 1myc-Hmg2p
using the cycloheximide chase assay.
 
Genetic Analysis
 
Cod
 
2
 
 candidates were crossed to the wild-type strain RHY542, to analyze
segregation of the mutant phenotype. All mutants were recessive and be-
longed to a single complementation group.
The wild-type 
 
COD1
 
 was cloned by plasmid complementation of a
 
cod1-1 
 
mutant with a 
 
URA3
 
, ARS-CEN library (Rose et al., 1987). Ura
 
1
 
transformants were tested for restoration of Cod
 
1
 
 phenotype using the
screening assays described above.
Plasmids recovered from the revertants were retested by transforma-
tion into the mutant strain. Insert flanks were sequenced and the se-
quences were compared with the 
 
Saccharomyces
 
 Genome Database.
Transformation of RHY811 (
 
cod1-1
 
) with plasmids pRH810 and pRH811
that contained only the 
 
COD1
 
 coding region rescued the Cod
 
2
 
 pheno-
type. Linkage of 
 
SPF1
 
 to 
 
cod-1
 
 was tested genetically by crossing a
Leu
 
2
 
cod1-1
 
 strain to a strain with 
 
LEU2
 
 (from pCS186) integrated in tan-
dem with functional 
 
COD1
 
 allele at the 
 
COD1 
 
locus. The resulting dip-
loid was sporulated to confirm anti-segregation of the Cod
 
2
 
 and Leu
 
1
 
phenotypes in the haploid progeny.
 
Growth Curves
 
Susceptibility of 
 
cod1-1
 
 to the mevalonate pathway inhibitors lovastatin,
L659,699, zaragozic acid and Ro48-8071 was tested in minimal media. Di-
lute liquid cultures of RHY791 or RHY811 used to serially dilute the
tested agent. The resulting cultures were incubated at 30
 
8
 
C and measured
at various times for optical density at 600 nm.
 
Results
 
The COD Screen
 
We designed a screen to identify 
 
cod 
 
mutants that could
not slow degradation of Hmg2p when degradation signals
from the mevalonate pathway were low. Specifically, we
isolated mutants that failed to stabilize Hmg2p upon treat-
 
Table I. Yeast Strains
 
Strain Genotype
 
RHY468
 
MAT
 
a
 
 hmg2::HIS3 ura3-52 LEU2
 
RHY541
 
MAT
 
a
 
 hmg2::HIS3::1mycHMG2 ura3-52::URA3::HMG2::GFP LEU2
 
RHY542
 
MATa hmg2::HIS3::1mycHMG2 ura3-52::URA3::HMG2::GFP LEU2
 
RHY555
 
MATa hmg2::HIS3 ura3-52::6MYC HMG2 hrd1-1 LEU2
 
RHY658
 
MAT
 
a
 
 hmg2::HIS3::1mycHMG2 ura3-52::URA3::HMG2::GFP LEU2 cod1-1
 
RHY660
 
MATa hmg2::HIS3::1mycHMG2 ura3-52::URA3::HMG2::GFP LEU2 cod1-1
 
RHY791
 
MAT
 
a
 
 hmg2::HIS3::1mycHMG2 ura3-52::URA3::HMG2::GFP
 
RHY792
 
MATa hmg2::HIS3::1mycHMG2 ura3-52::URA3::HMG2::GFP
 
RHY811 MATa hmg2::HIS3::1mycHMG2 ura3-52::URA3::HMG2::GFP cod1-1
RHY812 MATa hmg2::HIS3::1mycHMG2 ura3-52::URA3::HMG2::GFP cod1-1
RHY871 MATa hmg2::HIS3::1mycHMG2 ura3-52:LEU2::HMG2::GFP
RHY872 MATa hmg2::HIS3::1mycHMG2 ura3-52:LEU2::HMG2::GFP
RHY880 MATa hmg2::HIS3::1mycHMG2 ura3-52:LEU2::HMG2::GFP hrd1D::URA3
RHY910 MATa hmg2::HIS3::1mycHMG2 ura3-52:LEU2::HMG2::GFP cod1-1
RHY911 MATa hmg2::HIS3::1mycHMG2 ura3-52:LEU2::HMG2::GFP cod1-1 
RHY1056 MATa hmg2::HIS3::1mycHMG2 ura3-52:LEU2::HMG2::GFP ubc7D::URA3 
RHY1076 MATa hmg2::HIS3::1mycHMG2 ura3-52:LEU2::HMG2::GFP cod1-1 ubc7D::URA3 
RHY1077 MATa hmg2::HIS3::1mycHMG2 ura3-52:LEU2::HMG2::GFP cod1-1 ubc7D::URA3 
RHY1127 MATa hmg2::HIS3::1mycHMG2 ura3-52:LEU2::HMG2::GFP cod1-1 hrd1D::URA3 
RHY1128 MATa hmg2::HIS3::1mycHMG2 ura3-52:LEU2::HMG2::GFP cod1-1 hrd1D::URA3 
RHY1202 MATa hmg2::HIS3::1mycHMG2 ura3-52::URA3::HMG2::GFP cod1D::LEU2 
RHY1203 MATa hmg2::HIS3::1mycHMG2 ura3-52::URA3::K6RHMG2::GFP cod1-1 
RHY1205 MATa hmg2::HIS3::1mycHMG2 ura3-52::URA3::K6RHMG2::GFP 
RHY1473 MATa hmg2::HIS3::1mycHMG2 ura3-52::URA3::HMG1::GFP cod1-1 
RHY1475 MATa hmg2::HIS3::1mycHMG2 ura3-52::URA3::HMG1::GFP 
RHY1882 MATa hmg2::HIS3::1mycHMG2 ura3-52::URA3::6MYC HMG2::GFP 
RHY1883 MATa hmg2::HIS3::1mycHMG2 ura3-52::URA3::6MYC HMG2::GFP cod1D::LEU2 
RHY2201 MATa ura3-52::URA3::HMG2::GFP 
RHY2202 MATa pmr1D::LEU2 ura3-52::URA3::HMG2::GFP 
RHY2203 MATa spf1D::TRP1 ura3-52::URA3::HMG2::GFP 
RHY2204 MATa spf1D::TRP1 pmr1D::LEU2 ura3-52::URA3::HMG2::GFPThe Journal of Cell Biology, Volume 148, 2000 918
ment with lovastatin, an inhibitor of HMG-CoA reductase
that lowers these signals (Hampton and Rine, 1994; Gard-
ner and Hampton, 1999a). We identified these cod mutants
by scoring phenotypes resulting from the regulation of two
distinct versions of Hmg2p: Hmg2p-GFP, a noncatalytic
optical reporter of degradation, and 1myc-Hmg2p, an en-
zymatically active, epitope-tagged version of Hmg2p.
The optical reporter protein Hmg2p-GFP undergoes
normal, regulated degradation that can be observed by
examining cellular fluorescence by microscopy or flow
microfluorimetry (Hampton et al., 1996b; Cronin and
Hampton, 1999). Hmg2p-GFP was expressed from the
constitutive glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) promoter so that changes in the steady-state
level of the protein and the resultant cellular fluorescence
depended solely on changes in its degradation rate.
Hmg2p-GFP expressed in wild-type cells is stabilized
when the cells are treated with lovastatin, which lowers
degradation signals from the mevalonate pathway by in-
hibiting HMGR, leading to increased cellular fluorescence
(Cronin and Hampton, 1999; Gardner and Hampton,
1999a). A cod mutant unable to stabilize Hmg2p-GFP in
response to lowered regulatory signals would fail to in-
crease fluorescence in the presence of lovastatin. To score
such mutants, we used our previously described GFP col-
ony fluorescence assay (Cronin and Hampton, 1999).
Wild-type colonies expressing Hmg2p-GFP fluoresced
brightly when plated on media containing a small dose of
lovastatin (12.5 mg/ml), whereas cod mutants remained
dark even in the presence of lovastatin.
A second, independent phenotype of poor Hmg2p regu-
lation was also scored. We have shown that strains ex-
pressing only a poorly stabilized cis mutant of Hmg2p are
much more sensitive to lovastatin than otherwise isogenic
strains expressing normally regulated Hmg2p (Hampton
et al., 1996a; Gardner et al., 1998). Thus, constitutive
degradation of normal Hmg2p caused by a trans cod muta-
tion would similarly be expected to render the mutant
hypersensitive to lovastatin, compared with an isogenic
wild-type strain. The parent strain for the COD screen ex-
pressed the normally regulated 1myc-Hmg2p from a con-
stitutive promoter as its only source of HMGR activity
(Gardner et al., 1998). Misregulation of 1myc-Hmg2p by a
cod mutant was scored as hypersensitivity to lovastatin.
We combined the optical and pharmacological assays
described above using a strain coexpressing Hmg2p-GFP
and 1myc-Hmg2p. A successful cod candidate would be
dark when plated on a low dose of lovastatin and be hyper-
sensitive to the toxic effects of higher doses of lovastatin.
By screening for both phenotypes (see Materials and
Methods), we were able to rule out cis mutants of either
reporter, as well as trans mutants that affected processes
other than regulation of Hmg2p degradation. For exam-
ple, a mutant unable to stabilize Hmg2p-GFP upon lova-
statin treatment due to impermeability to lovastatin would
be dark, but would be resistant to lovastatin as opposed to
hypersensitive, and so would fail as a cod candidate.
COD1 Was Required for the Regulated Degradation
of Hmg2p
A total of .300,000 colonies were screened, from which
we isolated cod1-1 and 38 other members of the same
complementation group. In all assays the cod1-1 mutant
was defective in regulating Hmg2p-GFP degradation. In
wild-type cells, inhibition of the mevalonate pathway with
lovastatin stabilized Hmg2p-GFP resulting in increased
fluorescence which was seen by microscopy and flow mi-
crofluorimetry (Fig. 2, A and B). In contrast, addition of
lovastatin hardly increased the fluorescence of cod1-1 mu-
tant cells even though the concentration (25 mg/ml) used
in these experiments was .10 times that normally needed
to cause a maximal stabilization of Hmg2p-GFP (Gardner
et al., 1998; Cronin, S., unpublished observations). Unlike
lovastatin, addition of the squalene synthase inhibitor
zaragozic acid increases degradation of Hmg2p-GFP by
increasing a signal derived from the mevalonate pathway
product farnesyl pyrophosphate (Hampton and Bhakta,
1997; Gardner et al., 1998; Gardner and Hampton, 1999a).
Hmg2p regulation in cod1-1 mutants was also unrespon-
sive to zaragozic acid when compared with wild-type cells
(Fig. 2 B).
The cod1-1 mutant was hypersensitive to lovastatin, in-
dicating that the coexpressed 1myc-Hmg2p was also mis-
regulated. cod1-1 rendered cells 10 times more sensitive to
lovastatin than the isogenic wild-type cells (Fig. 2 C). In
contrast, the growth sensitivity of cod1-1 mutants to inhib-
itors of other pathway enzymes including HMG-CoA syn-
thase (L659,699), squalene synthase (zaragozic acid), or
oxidosqualene-lanosterol cyclase (Ro48-8071) remained
unchanged (Figs. 1 A and 2 C, and data not shown). These
results suggested that cod1-1 hypersensitivity to lovastatin
was due to misregulation of Hmg2p rather than any gen-
eral effects on pathway enzymes or other pleiotropic ac-
tions of the cod1-1 mutation.
We directly tested the ability of the cod1-1 mutant to
regulate Hmg2p degradation with cycloheximide chase as-
says. In these experiments, protein synthesis was blocked
at time zero by the addition of cycloheximide and degra-
Figure 1. Regulation of Hmg2p degradation by the mevalonate
pathway. (A) Increased production of FPP promotes Hmg2p
degradation. Relevant pathway intermediates are shown. Drugs
are shown above the enzymatic step that is inhibited (L659,
L659,699; LOVA, lovastatin; ZA, zaragozic acid; Ro, Ro48-
8071). Dotted arrows indicate multi-enzyme steps. (B) A model
for genes that control of Hmg2p degradation. Entry of Hmg2p
into the HRD-encoded ER degradation pathway is controlled by
COD genes in response to an FPP-derived signal.Cronin et al. Control of Hmg2p Degradation Requires COD1/SPF1 919
dation was allowed to proceed. 1myc-Hmg2p level was de-
termined by immunoblotting at various times to assess
degradation. Addition of lovastatin drastically slows the
degradation of 1myc-Hmg2p in wild-type cells (Hampton
and Rine, 1994; Fig. 3), whereas in cod1-1 lovastatin had
little or no effect.
COD1 Was Required for Regulation of
Hmg2p Ubiquitination
Ubiquitination is required for Hmg2p degradation and is
regulated in response to the same stimuli that control
Hmg2p stability. For example, treatment with zaragozic
acid increases Hmg2p ubiquitination and this effect is
blocked by simultaneous treatment with inhibitors of
upstream pathway enzymes such as HMG-CoA synthase
(Hampton and Bhakta, 1997; Gardner et al., 1998). We
examined the regulation of Hmg2p ubiquitination in
cod1-1 mutants. Hmg2p ubiquitination was assayed by
coimmunoprecipitation using strains expressing HA epi-
tope-tagged ubiquitin (Gardner et al., 1998). Hmg2p was
immunoprecipitated with polyclonal antibodies, then im-
munoblotted for HA immunoreactivity to evaluate ubiq-
uitination or for MYC immunoreactivity to evaluate the
total amount of Hmg2p precipitated. In wild-type cells
ubiquitination of Hmg2p was regulated as previously re-
ported: brief treatment with zaragozic acid increased ubiq-
uitination of Hmg2p, and this effect of zaragozic acid was
blocked by pretreatment with the HMG-CoA synthase in-
hibitor L659,699 (see Fig. 4; Hampton and Bhakta, 1997).
In contrast, Hmg2p ubiquitination was uniformly higher in
the cod1-1 mutant, and was unaffected by the addition of
either zaragozic acid or L659,699, consistent with the con-
stitutive, unregulated degradation of the two Hmg2p re-
porters.
ER Degradation Mutants Stabilized Hmg2p in cod1-1
We have proposed a model in which the COD genes regu-
lating Hmg2p degradation are distinct from the genes en-
coding the ER degradation machinery (Fig. 1). This model
predicts that the unregulated degradation of Hmg2p in a
cod1-1 mutant would still be blocked in hrd mutants,
which are deficient in Hmg2p degradation. To test this
model, we constructed strains with the cod1-1 mutation
and null mutations in HRD1 or UBC7, each are essential
Figure 2. cod1-1 prevented regulation of Hmg2p-GFP level and
caused lovastatin hypersensitivity. (A) Regulation of Hmg2p-
GFP stability in wild-type or cod1-1 cells. Early log phase cul-
tures were allowed to grow for 4 h in the presence or absence of
25 mg/ml lovastatin (LOVA). Each panel shows equivalent num-
bers of cells, photographed with identical optical settings. (B)
Regulation of Hmg2p-GFP level examined by flow microfluorim-
etry. Cultures of wild-type or cod1-1 cells were grown for 4 h
without drugs or in the presence of lovastatin or zaragozic acid
(ZA) as indicated and then subjected to flow microfluorimetry.
Each histogram represents 10,000 cells. (C) Growth arrest of
wild-type and cod1-1 cells by mevalonate pathway inhibitors.
Low density (OD600 , 0.01) cultures were allowed to grow for 2.5 d
in the indicated concentrations of lovastatin or L659,699. Final
OD600 readings were taken for each concentration and plotted as
percent of the appropriate untreated culture. Representative ex-
periments are shown.
Figure 3. cod1-1 disrupted regulation of 1myc-Hmg2p degrada-
tion. Wild-type or cod1-1 cells were examined for degradation of
1myc-Hmg2p by addition of cycloheximide at time 0, followed by
lysis at the indicated time (0 or 4 hours), and anti-myc immuno-
blotting. Lovastatin (L) was added to the indicated samples at the
same time as cycloheximide.
Figure 4. Ubiquitination of
Hmg2p was unregulated in
cod1-1 cells. Wild-type or
cod1-1 cells expressing HA-
tagged ubiquitin were grown
in the presence or absence of
the indicated drugs. L659,699
(L6) was added 30 min before
lysis and zaragozic acid (ZA)
was added 10 min before lysis.
The cultures were lysed,
Hmg2p was immunoprecipi-
tated with antibodies against
Hmg2p and then immuno-
blotted following SDS-PAGE. Ubiquitinated Hmg2p was de-
tected by anti-HA immunoblotting, and total Hmg2p was de-
tected by anti-myc immunoblotting.The Journal of Cell Biology, Volume 148, 2000 920
for Hmg2p degradation (Hampton and Bhakta, 1997;
Hampton et al., 1996a). Deletion of either UBC7 or HRD1
greatly increased Hmg2p-GFP fluorescence in both wild-
type and cod1-1 mutants as measured by microscopy (Fig.
5 A) or flow microfluorimetry (Fig. 5 B). The hrd1D and
ubc7D null mutations completely blocked the constitutive
degradation caused by the cod1-1 mutation, such that fluo-
rescence histograms of the double mutants were superim-
posable with the histograms of the hrd1D and ubc7D single
mutants (Fig. 5 B). The stability of Hmg2p-GFP in each
strain was directly tested by addition of cycloheximide fol-
lowed by flow microfluorimetry to evaluate loss of cellular
fluorescence due to Hmg2p-GFP degradation. This loss of
fluorescence was completely inhibited by the presence of
ubc7D (middle panels) or hrd1D (right panels). ubc7D
(Fig. 5 C) or hrd1D (data not shown) also blocked degra-
dation of 1myc-Hmg2p.
Degradation of Other ER Proteins in cod1-1
The cod1-1 mutation removed regulation of Hmg2p, ren-
dering its degradation constitutive. We wanted to deter-
mine if cod1-1 mutation generally altered the stability of
ER proteins. Accordingly, we examined the effect of the
cod1-1 mutation on the stable, ER localized Hmg1p-GFP
reporter protein derived from the HMGR isozyme Hmg1p
(Hampton and Rine, 1994; Hampton et al., 1996b; Gard-
ner et al., 1998). In both wild-type and cod1-1 strains
Hmg1p-GFP remained stable during the 4 h of an optical
cycloheximide chase (Fig. 6 A). Hmg1p-GFP was stable in
the cod1-1 mutant under all conditions tested for Hmg2p-
GFP indicating that the cod1-1 mutation does not promote
degradation of this normally stable ER protein.
Figure 5. Hmg2p in cod1-1 was stabilized by ER degradation
mutants. (A) Hmg2p-GFP fluorescence of wild-type or mutant
cells was examined by fluorescence microscopy. Cells in the top
row of panels are wild-type for COD1 and cells in the bottom
row have the cod1-1 mutation. Cells in the middle and right col-
umns have ubc7D or hrd1D null alleles, respectively. Equivalent
numbers of cells were photographed in each panel using identical
settings. (B) Degradation of Hmg2p-GFP was examined by flow
microfluorimetry in wild-type or cod1-1 cells with or without
ubc7D or hrd1D as labeled. Cycloheximide (CHX) was added to
the indicated cultures 4 h before analysis. (C) 1myc-Hmg2p deg-
radation in wild-type, cod1-1, ubc7D, and cod1-1/ubc7D cells was
assayed by cycloheximide chase. After addition of cycloheximide
samples were lysed at 0 or 4 h followed by SDS-PAGE and im-
munoblotting of the lysates. Lovastatin (L) was added to the indi-
cated samples at the same time as cycloheximide.
Figure 6. The stability of other ER membrane proteins in Cod2
cells. (A) Wild-type and cod1-1 cells expressing either Hmg2p-
GFP or Hmg1p-GFP were assayed by flow microfluorimetry for
loss of fluorescence after 4-h incubation in the presence or ab-
sence of cycloheximide (CHX). (B) The stability of 6myc-
Hmg2p-GFP in wild-type and cod1D cells was assayed by cyclo-
heximide chase. After addition of cycloheximide samples were
lysed at various times followed by SDS-PAGE and immunoblot-
ting of the lysates. (C) The K6R mutation enhances Hmg2p-GFP
stability in cod1-1. Wild-type and cod1-1 cells expressing either
Hmg2p-GFP or the K6R variant of Hmg2p-GFP were assayed by
flow microfluorimetry for loss of fluorescence after 4-h incuba-
tion in the presence or absence of cycloheximide (CHX).Cronin et al. Control of Hmg2p Degradation Requires COD1/SPF1 921
We also tested the effect of COD1 mutation on the sta-
bility of a short-lived, unregulated variant of Hmg2p,
6myc-Hmg2p-GFP (Hampton et al., 1996a), by cyclohex-
imide chase (Fig. 6 B). In both wild-type and cod1D cells,
6myc-Hmg2p-GFP was degraded rapidly with an esti-
mated half-life of less than an hour, though it appeared to
be slightly more abundant in the Cod2 cells. In similar ex-
periments, we found that the degradation rate of the regu-
lated 1myc-Hmg2p did not differ substantially between
wild-type and Cod2 cells in the absence of mevalonate
pathway inhibitors (data not shown). Clearly, cod1 muta-
tion did not generally affect the stability of ER proteins.
Rather, it specifically affected the feedback regulation
of Hmg2p degradation by signals from the mevalonate
pathway.
Recognition of cis Determinants for Hmg2p-regulated 
Degradation in cod1-1
Recently, we have shown that the regulated degradation
of Hmg2p is critically dependent on two lysines in the
transmembrane region of the protein. Replacement of ei-
ther lysine 6 or lysine 357 of Hmg2p with arginine (or any
other amino acid) strongly stabilizes Hmg2p or Hmg2p-
GFP (Gardner and Hampton 1999b). Furthermore, the
function of these lysines is extremely sensitive to alter-
ations in Hmg2p structure. Since these lysines play a criti-
cal role in regulation of stability, we wondered if they
would still function in a cod1-1 background. In both cod1-1
and wild-type genetic backgrounds, the K6R mutant of
Hmg2p-GFP was more stable than wild-type Hmg2p,
though some degradation is apparent in the cod1-1 mutant
(Fig. 6 C). The same result was seen with the K357R re-
placement, and with the double mutant (data not shown).
These data indicated that the degradation of Hmg2p in a
cod1-1 mutant was still largely dependent on the same cis
determinants that are necessary for regulating Hmg2p
degradation in a wild-type cell. However, the incomplete
stability of the K6R mutant in cod1-1 suggested that
Cod1p has a subtle effect on the structure of Hmg2p or the
recognition of its distributed degron (Gardner and Hamp-
ton, 1999b).
COD1 Encoded a P-Type ATPase
The wild-type COD1 gene was isolated by plasmid library
complementation of the cod1-1 mutation and was shown
by linkage analysis to be YEL031w, previously isolated as
SPF1 (sensitivity to Pichia farinosa). We deleted COD1 in
a haploid strain and the null mutant was viable. In all as-
says for regulation of Hmg2p degradation, the cod1D mu-
tant behaved exactly as the cod1-1 mutant (Fig. 7, data not
shown). Additionally, overexpression of COD1 from a 2m
plasmid failed to produce any observable change in regu-
lation of Hmg2p levels.
COD1 belongs to a large family of genes encoding
P-type ATPases that actively transport various ions
across membranes (Catty et al., 1997; Axelsen and Palm-
gren, 1998). The yeast genome encodes 16 members of
this family with the uncharacterized open reading frame
YOR291w being most similar to Cod1p  (26% identity,
44% similarity across 1,124 amino acids of homology). De-
letion of YOR291w failed to produce any obvious pheno-
types or affect regulation of Hmg2p degradation. Double
mutants carrying deletions of both YOR291w and COD1
were viable and retained the Cod2 phenotype without any
enhancement or suppression (data not shown). Evidently,
despite the high homology between the two proteins, only
Cod1p functioned in Hmg2p regulation.
The more distantly related P-type ATPase Pmr1p (22%
identity, 39% similarity across 733 amino acids of homol-
ogy) has recently been implicated in the degradation of
the misfolded ER lumenal protein CPY*. Deletion of
PMR1 prevents the degradation of CPY* by the ubiquitin
proteasome pathway (Duerr et al., 1998). We examined
the effect of pmr1D on Hmg2p-GFP degradation and
found that Hmg2p-GFP stability was identical in an iso-
genic series including wild-type, pmr1D, cod1D, and pmr1D/
cod1D strains (Fig. 7 A).
We tested the effects of pmr1D on Hmg2p-GFP regula-
tion. In the wild-type H2071 genetic background used in
these studies, Hmg2p-GFP degradation was relatively
slow, but could be hastened by the addition of zaragozic
acid (Fig. 7 B). While the response of Hmg2p-GFP to
zaragozic acid was severely blunted in cod1D, Hmg2p-
Figure 7. Deletion of PMR1
did not affect the regulated
degradation of Hmg2p-GFP.
(A) Stability of Hmg2p-GFP
in wild-type, cod1D,  pmr1D,
and cod1D/pmr1D cells. Early
log phase cultures were grown
for 4 h in the presence or ab-
sence of cycloheximide (CHX)
and subjected to flow micro-
fluorimetry. (B) Regulation
of Hmg2p-GFP degradation
in wild-type, cod1D,  pmr1D,
and cod1D/pmr1D cells. Early
log phase cultures were grown
for 4 h in the presence or ab-
sence of zaragozic acid (ZA)
and subjected to flow micro-
fluorimetry.The Journal of Cell Biology, Volume 148, 2000 922
GFP degradation was regulated normally in pmr1D. Inter-
estingly, the defective regulation of Hmg2p seen in cod1D
was partially suppressed by simultaneous deletion of
PMR1  suggesting that Pmr1p and Cod1p may both play a
role in Ca21 homeostasis, though in distinctly different
ways.
Manipulating Ca21 Affected Regulation of
Hmg2p Stability
Phenotypic defects in some yeast P-type ATPase mutants
can be overcome or exacerbated by manipulating the con-
centration of ions in the growth media (Duerr et al., 1998;
Suzuki and Shimma, 1999). We examined the effect of
such manipulations on the cod1-1 mutant and wild-type
strains. Incubation of a cod1 deletion mutant in 200 mM
CaCl2 partially restored regulation of Hmg2p-GFP (Fig.
8). No other ions similarly tested (MnCl2, CaCl2, KCl, or
NaCl) restored regulation of Hmg2p-GFP degradation.
The high concentration of CaCl2 also caused a drop in the
pH of the growth media, but lowering the pH of the media
with HCl instead of CaCl2 failed to produce any effect
(data not shown).
We also tested the effect of Ca21 depletion on regula-
tion of Hmg2p stability in wild-type cells by treatment
with EGTA, a chelator of divalent ions with high Ca21
specificity (Fig. 9). Overnight treatment with a sub-lethal
concentration of EGTA blunted the regulatory responses
to both lovastatin and zaragozic acid when compared with
untreated cells. These effects of EGTA treatment were
overcome by addition of CaCl2, but not MgCl2. These ex-
periments with EGTA were consistent with a role for
CaCl2 in the regulation of Hmg2p degradation. However,
EGTA treatment of wild-type cultures did not fully mimic
the Cod2 phenotype and significantly reduced growth
(data not shown) indicating that the effects of COD1 were
more specific for Hmg2p degradation than those caused
by gross Ca21 depletion.
Discussion
The striking cis and trans specificity of Hmg2p stability
regulation led us to posit that this process involves a sepa-
rate set of genes referred to as COD genes. In this work,
we have isolated the first member of this class of genes.
We focused our search on cod mutants that always de-
grade Hmg2p even when signals for degradation are low.
By our model (Fig. 1), Hmg2p degradation in such a cod
mutant would still be halted by mutations in genes encod-
ing the degradation machinery, such as a hrd1 mutant.
The resulting mutant, cod1-1, had the desired pheno-
type: Hmg2p and Hmg2p-GFP each undergo constitutive
degradation that is largely refractory to regulatory signals.
Despite the lack of regulation, Hmg2p in the cod1 mutant
was degraded at roughly the same rate as in the wild-type
under normal growth conditions. Importantly, the consti-
tutively degraded Hmg2p in a cod1 mutant was strongly
stabilized by the simultaneous presence of a hrd1 or ubc7
mutant, showing that indeed regulation can be uncoupled
from degradation. The cod1 mutant did not globally alter
the stability of ER proteins, since cod1 mutation neither
destabilized the normally stable Hmg1p-GFP nor altered
the degradation rate of the misfolded, constitutively de-
graded 6myc-Hmg2p-GFP.
The degradation of Hmg2p can be slowed with drugs
that block early in the mevalonate pathway or hastened
by inhibition of squalene synthase with zaragozic acid (Hamp-
ton and Rine, 1994; Hampton and Bhakta, 1997; Gardner
and Hampton, 1999a). Both actions arise from alteration
of the mevalonate-derived molecule farnesyl pyrophos-
phate (FPP; Gardner and Hampton, 1999a). The cod1 mu-
tants showed strongly blunted responses to both lovastatin
and zaragozic acid. Thus, COD1 is required for coupling
the rate of Hmg2p degradation to levels of the FPP-derived
signal.
Cod1p is a P-type ATPase. Members of this widely con-
served family function in ATP-dependent pumping of ions
across biological membranes. The ion specificity of a given
P-type ATPase can not yet be determined from sequence
information alone. However, our studies indicate that
Cod1p may be a Ca21 transporter. The cod1 phenotype is
reversed by addition of Ca21 to the growth medium of mu-
tant cells, and no other divalent ions tested could do this.
Furthermore, treatment of wild-type cells with the Ca21-
preferring chelator EGTA caused aberrant regulation that
was similar to the Cod12 phenotype, and specifically re-
versed by calcium.
Figure 8. CaCl2 restored control of degradation to cod1-1. Wild-
type or cod1D cells were grown overnight in the presence or ab-
sence of 200 mM CaCl2. Lovastatin (lova) was added to the indi-
cated cultures 4 h before analysis by flow microfluorimetry.
Figure 9. EGTA blunted
regulation of Hmg2p-GFP
levels in a Ca21-dependent
manner. Cells expressing
Hmg2p-GFP were assayed
for regulation of fluores-
cence after overnight growth
in the presence or absence
780 mM EGTA. Lovastatin
(lova), zaragozic acid (ZA),
and/or CaCl2 were added 4 h
before analysis.Cronin et al. Control of Hmg2p Degradation Requires COD1/SPF1 923
This connection between calcium and HMGR regula-
tion is especially intriguing given that regulated degrada-
tion of HMGR in mammals is similarly sensitive to per-
turbations of cellular calcium (Roitelman et al., 1991;
Roitelman and Simoni, 1992). In mammalian cells Ca21
deprivation specifically inhibits the action of the degrada-
tion signal derived from FPP (Roitelman and Simoni,
1992; Meigs et al., 1996). Similarly, cod1-1 mutants cannot
respond to the FPP-derived signal for Hmg2p degradation.
Cod1p appeared to have a fairly specific function. The
COD1 gene is not essential and the viable cod1D null mu-
tant has a phenotype identical to that of the cod1-1 allele.
A null mutation in COD1’s closest paralogue, YOR291w,
had no observable effect on yeast growth or Hmg2p regu-
lation, alone or in combination with the cod1D null. Our
ongoing studies have localized the Cod1p protein to the
ER (Cronin, S.R., and R.Y. Hampton, manuscript in prep-
aration), and our current model is that Cod1p is a Ca21
transporter that is important for establishing a lumenal en-
vironment appropriate for control of Hmg2p stability.
Changes to the ER environment in a cod1 mutant might
alter Hmg2p stability by affecting the presentation of the
highly specific structural determinants needed for regu-
lated degradation (Gardner and Hampton, 1999b). Alter-
natively, Cod1p activity may be critical for the function of
trans factors regulating Hmg2p degradation.
A model in which Cod1p functions in the ER might ex-
plain some of the other phenotypes reported for cod1 mu-
tants. COD1 was previously identified as SPF1 in an ap-
parently unrelated screen for mutants resistant to a killer
toxin. Other phenotypes reported for spf1D null mutants
include defective glycosylation of invertase, resistance to
vanadate, and sensitivity to hygromycin and calcofluor
white (Suzuki and Shimma, 1999). The sensitivity to hy-
gromycin and calcofluor white, indicating defective cell
wall synthesis, and the defective glycosylation of invertase
all support a role for Cod1p in maintaining the lumenal
environment of the ER, an environment thought to be
controlled principally by PMR1.
The Golgi-localized P-type ATPase Pmr1p is thought to
play a major role in maintaining Ca21 levels in the secre-
tory pathway (Strayle et al., 1999). PMR1 is required for
numerous ER functions and has recently been identified
as DER5, a gene necessary for the degradation of the mis-
folded lumenal protein CPY* (Duerr et al., 1998). In con-
trast to the effect of pmr1D on CPY* degradation, pmr1D
had no effect on Hmg2p degradation or its feedback regu-
lation. Thus, Pmr1p and Cod1p appear to have distinct
roles, at least in this ER function. There are metazoan
P-type ATPase family members of unknown function that
have higher similarity to COD1 than to PMR1. It is tempt-
ing to speculate that they may have similar, specialized
functions in a variety of organisms.
We currently do not know the mechanism of regulated
stability, and one possibility is that there are proteins that
specifically protect Hmg2p from degradation when degra-
dation signals are lowered. If such protection factors exist,
they would be particularly important both in the basic un-
derstanding of regulated ER degradation, and as possible
targets for cholesterol lowering drugs. Loss of a protection
factor by mutation would cause signal-independent, con-
stitutive degradation of Hmg2p, and so would score as
a cod candidate, like cod1-1. However, .300,000 muta-
genized colonies of the parent strain were screened yet
only alleles (39) of COD1 were recovered. Thus, it may be
that the mechanism of Hmg2p regulation does not involve
protection factors. Alternatively, it is possible that this
version of the COD screen was biased towards recovery of
COD1 alleles.
In summary, the above work demonstrates that the ge-
netic approach to understanding regulated degradation of
HMGR is a viable one. Integration of the COD1 gene’s
function into the scenario of Hmg2p regulation and ER
function will be an important aspect of completing the pic-
ture of HMGR regulated degradation, in yeast and most
likely in other eukaryotes as well.
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